• October 4, 2022

  EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
  TO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS

• September 28, 2022

  LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE

• September 26, 2022

  Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange
  (Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act)

• September 26, 2022

  METOJECT® SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS

• September 21, 2022

  RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER’S DAY, SEPTEMBER 21
  “LEARNING HELPS US TO BE KIND” LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP

View All

• September 29, 2022

  Wednesday, September 28, 2022 15:00 - (JST)
  <Eisai Media/Investor Conference>
  LECANEMAB PHASE 3 STUDY MET PRIMARY ENDPOINT [Material, Webcast]

• September 13, 2022

  IR “Value Creation Report 2022”

• August 8, 2022

  IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2023 [Material, Webcast]”

• August 5, 2022

  IR “First Quarter Financial Report for the Fiscal Year Ending March 31, 2023”

View All

• July 15, 2022

  Notification Regarding U.S. Research and Development Subsidiary

• April 1, 2022

  Humanitarian Support to Ukraine

• November 24, 2021

  Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

• September 22, 2021

  EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY

• April 19, 2021

  Eisai formulates the action plan “Diversity & Inclusion 2021”

View All